456 Studies Now Enrolling
A PHASE IIA MULTICENTER, OPEN-LABEL, 12-WEEK STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY AND TO PROVIDE PROOF OFMECHANISM OF ALOGABAT IN CHILDREN AND ADOLESCENTS AGED 517 YEARS WITH ANGELMAN SYNDROME (AS) WITH DELETION GENOTYPE
Study of Alogabat in Children and Adolescents with Angelman Syndrome (AS)
| Sponsor: | F. Hoffman La Roche Ltd |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAU5011 |
| Contact: | Jennifer Bain: / jb3634@cumc.columbia.edu |
Additional Study Information:
This is a Phase IIA Multicenter, open-label, 12-week study to investigate the pharmacokinetics and safety and to provide proof of mechanism of the drug, Alogabat (RO7017773) in children and adolescents aged 5-17 years old with Angelman Syndrome with the deletion genotype.
